Fluorescein- and EGFR-Antibody Conjugated Silica Nanoparticles for Enhancement of Real-time Tumor Border Definition Using Confocal Laser Endomicroscopy in Squamous Cell Carcinoma of the Head and Neck

Watermann, Anna; Gieringer, Rita; Bauer, Anna-Maria; Kurch, Sven; Kießlich, Ralf; Tremel, Wolfgang; Gosepath, Jan; Brieger, Juergen

doi:10.3390/nano9101378

Cited by 20 publications

(17 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, it was reported that MSNs may reduce the amounts of endogenous ROS leading to enhanced malignant melanoma growth . Also, accumulation of MSNs in normal body organs, specially the liver and spleen is an issue that needs to be addressed before further translation of MSNs into clinical practice …”

Section: Applications Of Msnsmentioning

confidence: 99%

Multidisciplinary Role of Mesoporous Silica Nanoparticles in Brain Regeneration and Cancers: From Crossing the Blood–Brain Barrier to Treatment

Mendiratta

Hussein

Nasser

et al. 2019

Part & Part Syst Charact

View full text Add to dashboard Cite

that by 2040, neurodegenerative diseases will surpass cancer as the second reason of death after cardiovascular diseases in such aged populations. [1,2] As per a 2017 report, neurological diseases cost the United States of America about $800 billion annually and this number is expected to increase even further over the coming years as the percentage of aged citizens increases. [3] Unlike most other major diseases, the pace of drug development and delivery in case of neurodegenerative diseases has been stationary, partially due to lack of biomarkers that can diagnose such diseases long before the neurological symptoms arise and the challenges associated with identification of targets for drugs that can terminate or minimize neurodegeneration. Most importantly, delivering new cerebral therapeutic agents is impeded by the extensive and robust blood-brain barrier (BBB) which prevents the vast majority of drugs from crossing to the brain after systemic administration. During brain infections, intracerebral hemorrhage, or in neurodegenerative disorders, the BBB is altered in such a way that it allows easy access of inflammatory inducing molecules that may cause adverse neuronal damage. [4] Given the importance of early diagnosis and treatment of neurodegenerative diseases, new drug delivery technologies have appeared in the last decade.As shown in Scheme 1, unique nanomaterials have been reported and several nanosized drug delivery systems including liposomes, dendrimers, carbon nanotubes (CNTs), inorganic and hybrid nanoparticles, and polymeric micelles have gained attention and have been tested for targeted drug delivery not only for neurodegenerative diseases but also for several other ailments. [5][6][7][8][9][10] The discovery of MCM-41 was recognized as a major breakthrough in materials science and since then mesoporous silica nanoparticles (MSNs), thanks to their superior physiochemical properties such as large porosity, high surface areas, low toxicity, controllable sizes, and wide range of morphologies compared to conventional nanoparticles (NPs) have emerged as favorable tools in biomedical applications as nanocarriers for encapsulation and delivery of therapeutic medicines. [11][12][13][14] Designing biocompatible MSNs and their multifunctional derivatives for drug transport as well as theranostics is one of the hottest areas of research in the field of nanobiotechnology and nanomedicine. [15][16][17][18][19] High loading capacity, acceptable biocompatibility, and limitless possibilities of surface functionalization for specific cellular recognition Mesoporous silica nanoparticles (MSNs) have gained wide attention for their role in biomedicine and as drug delivery vehicles. Their structural tunability, high surface area, and easy functionalization impart significant advantages over conventional materials. In this Review, recent advances in the synthesis, drug delivery, and therapeutic roles of MSNs in the treatment of various neurodegenerative and neuroinflammatory diseases are presented. The intention is to...

show abstract

Section: Applications Of Msnsmentioning

confidence: 99%

Multidisciplinary Role of Mesoporous Silica Nanoparticles in Brain Regeneration and Cancers: From Crossing the Blood–Brain Barrier to Treatment

Mendiratta

Hussein

Nasser

et al. 2019

Part & Part Syst Charact

View full text Add to dashboard Cite

show abstract

“…In any nanocarrier system designed for in vivo applications, the toxicity of the nanoparticles is one of critical issues that needs to be extensively investigated. Although many reports from the literature showed that the applications of MSN‐based nanocarriers possess low or negligible in vivo systemic toxicity profile, it was revealed in a review paper reported by Brinker et al . that there is a consensus about the undesired toxicity that might be associated with the application of MSN‐based nanocarriers is mainly due to the availability of highly reactive surface silanol (SiOH) functional groups.…”

Section: Various Types Of Nanoparticles For Therapeutic Nanoreactors mentioning

confidence: 99%

Therapeutic Nanoreactors as In Vivo Nanoplatforms for Cancer Therapy

Mukerabigwi

Kataoka

2018

Chemistry A European J

View full text Add to dashboard Cite

Therapeutic nanoreactors have been proposed as nanoplatforms to treat diseases through in situ production of therapeutic agents. When this treatment strategy is applied in cancer therapy, it can efficiently produce highly toxic anticancer drugs in situ from low-toxic prodrugs or some biomolecules in tumor tissues, which can maximize the therapeutic efficacy with a significantly low systemic toxicity. An ideal therapeutic nanoreactor can provide the reaction space, protect the loaded fragile catalysts, target the desired pathological site, and be selectively activated. In this minireview, we highlight the recent advances concerning the applications of therapeutic nanoreactors as in vivo nanoplatforms particularly in cancer therapy. Herein, the therapeutic nanoreactors are discussed on the basis of treatment strategies and various nanoparticles. Specifically, the treatment strategies of nanoreactors including single enzyme, single enzyme with chemodrugs, and multienzymes, as well as varying types of engineered nanoparticle-loaded active catalysts, primarily including liposomes, polymersomes, polymeric micelles, inorganic nanoparticles, and metal-organic framework (MOF) architectures, are documented and briefly discussed. Finally, we elucidate the current challenges to be addressed toward further development and translation into clinical applications of these therapeutic nanoreactors in cancer therapy.

show abstract

“…Silica nanoparticle has a wild range of applications in bio‐nanotechnology due to their physical, chemical, and optical properties such as chemical modification diversity, biocompatibility, optical transparency, low toxicity, and particle‐size tunability [14] . Silica nanoparticles are mostly used in drug delivery, [15] biosensors, [16] and bio‐imaging [17] . Mesoporous silica nanoparticles (MSNPs) own a unique structure with an adjustable pore and particle size, leading to a large specific surface area which can be easily functionalized.…”

Section: Introductionmentioning

confidence: 99%

Fluorescent Mesoporous Nanoparticles for β‐Lactamase Screening Assays

Tummala

Huang

et al. 2020

ChemistryOpen

View full text Add to dashboard Cite

We present a sensitive and rapid screening method for the determination of β‐lactamase activity of antibiotic‐resistant bacteria, by designing a pH‐sensitive fluorescent dye‐doped mesoporous silica nanoparticle encapsulated with penicillin G as a substrate. When penicillin G was hydrolysed by β‐lactamase and converted into penicilloic acid, the acidic environment resulted in fluorescence quenching of the dye. The dye‐doped mesoporous nanoparticles not only enhanced the β‐lactamase‐catalyzed reaction rate but also stablized the substrate, penicillin G, which degrades into penicilloic acid in a water solution without β‐lactamase. Twentyfive clinical bacterial samples were tested and the antibiotic resistant and susceptible strains were identified. The proposed method may detect the presence of β ‐lactamases of clinically relevant samples in less than 1 hour. Moreover, the detection limit of β‐lactamase activity was as low as 7.8×10−4 U/mL, which was determined within two hours.

show abstract

Fluorescein- and EGFR-Antibody Conjugated Silica Nanoparticles for Enhancement of Real-time Tumor Border Definition Using Confocal Laser Endomicroscopy in Squamous Cell Carcinoma of the Head and Neck

Cited by 20 publications

References 17 publications

Multidisciplinary Role of Mesoporous Silica Nanoparticles in Brain Regeneration and Cancers: From Crossing the Blood–Brain Barrier to Treatment

Multidisciplinary Role of Mesoporous Silica Nanoparticles in Brain Regeneration and Cancers: From Crossing the Blood–Brain Barrier to Treatment

Therapeutic Nanoreactors as In Vivo Nanoplatforms for Cancer Therapy

Fluorescent Mesoporous Nanoparticles for β‐Lactamase Screening Assays

Contact Info

Product

Resources

About